Based on our Pharmacor Venous Thromboembolism advisory service, Decision Resources is offering an exclusive analyst call entitled Venous Thromboembolism: How Will Sanofi-Aventis’s Semuloparin (AVE-5026) Compete in a Market That Will Soon Feature a Range of Oral Anticoagulants? Because this presentation features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.

Recorded live on Monday, July 26, 2010

This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., answers the following questions:

• In a market that will soon feature a range of oral anticoagulants, how can semuloparin compete against these therapies and gain traction in the market?
• As ongoing Phase III trials of semuloparin examine the drug in specific patient populations, what levels of competition from current and emerging therapies could semuloparin face in these indications?
• What challenges remain for the continued clinical development of semuloparin?

Contact us to learn how you can purchase this service and access a recorded playback of this event.

Click here to view the invite.